Nitazoxanide added to usual care for mild-to-moderate ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests whether adding nitazoxanide, an anti-parasitic medicine, to your current ulcerative colitis treatment helps reduce inflammation and symptoms. It may offer an extra option for people with mild-to-moderate disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had ulcerative colitis for at least 6 months.
- Your disease is mild to moderate (based on a standard scoring system).
- You have been on a stable treatment plan for ulcerative colitis for at least 8 weeks.
- You do not have a severe flare requiring hospitalization or surgery.
- You have not taken antibiotics, probiotics, or experimental drugs in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (cizutamig) for people with moderate to severe ulcerative colitis that hasn't responded well to standard treatments. It aims to see if the drug can reduce inflammation and improve symptoms.
This trial tests a new medicine, ENC1018, taken by mouth, for people with moderate to severe ulcerative colitis (UC) that hasn't improved with standard treatments. The goal is to see if it's safe and helps reduce symptoms.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.